New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq
Retrieved on:
Friday, December 10, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Oncology, Risk, Neoplasm, Population, Patient, Immunotherapy, Pain, ESMO, European Society for Medical Oncology, Phase, TPS, PFS, AES, Safety, Lung cancer, Progression-free survival, Pros, Quality of life, Food, Death, ROG, Lung, Rash, Cancer, Breathe Me, RO, Fatigue, EORTC, Breakthrough therapy, BTD, Esophageal cancer, Hematological Cancer Research Investment and Education Act, Abstract, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hoffmann-La Roche, NE, NSCLC, OS, ITT, Pharmaceutical industry, the CITYSCAPE study1, tiragolumab, lung cancer, Tecentriq® (atezolizumab), Genentech in cancer immunotherapy, Genentech in lung cancer, Genentech, THE CITYSCAPE STUDY1, TIRAGOLUMAB, LUNG CANCER, TECENTRIQ® (ATEZOLIZUMAB), GENENTECH IN CANCER IMMUNOTHERAPY, GENENTECH IN LUNG CANCER, GENENTECH
After 2.5 years median follow-up, tiragolumab plus Tecentriq continued to show an improvement in the intention-to-treat (ITT) population (n=67), driven by the PD-L1-high population (TPS 50%) (n=29).
Key Points:
- After 2.5 years median follow-up, tiragolumab plus Tecentriq continued to show an improvement in the intention-to-treat (ITT) population (n=67), driven by the PD-L1-high population (TPS 50%) (n=29).
- Since 2020, Genentech has initiated five Phase III trials evaluating tiragolumab plus Tecentriq in early and metastatic disease in lung (SKYSCRAPER-01, SKYSCRAPER-02, SKYSCRAPER-03) and esophageal cancers (SKYSCRAPER-07, SKYSCRAPER-08).
- CITYSCAPE is a global Phase II, randomized and blinded study evaluating tiragolumab plus Tecentriq (atezolizumab) compared with Tecentriq alone in 135 patients with first-line PD-L1-positive locally advanced, unresectable or metastatic non-small cell lung cancer.
- Patients were randomized 1:1 to receive either tiragolumab plus Tecentriq or placebo plus Tecentriq, until progressive disease or loss of clinical benefit.